Captrust Financial Advisors Innoviva, Inc. Transaction History

Captrust Financial Advisors

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 23, 2022	SELL	$14.32 - $19.88 $787 - $1,093	-55 Reduced 1.94%	2,773 $41,000
Q2 2022 Aug 16, 2022	BUY	$14.32 - $19.88 $1,847 - $2,564	129 Added 4.78%	2,828 $42,000
Q1 2022 May 16, 2022	BUY	$15.39 - $20.25 $32,549 - $42,828	2,115 Added 362.16%	2,699 $52,000
Q4 2021 Feb 14, 2022	SELL	$15.91 - $18.72 $5,743 - $6,757	-361 Reduced 38.2%	584 $10,000
Q3 2021 Nov 16, 2021	BUY	$13.06 - $17.24 $848 - $1,120	65 Added 7.39%	945 $16,000
Q2 2021 Aug 16, 2021	BUY	$11.45 - $13.96 $458 - $558	40 Added 4.76%	880 $12,000
Q1 2021 May 17, 2021	BUY	$11.06 - $12.87 $7,907 - $9,202	715 Added 572.0%	840 $10,000
Q4 2020 Feb 16, 2021	BUY	$9.33 - $12.48 $419 - $561	45 Added 56.25%	125 $2,000
Q3 2020 Nov 17, 2020	BUY	$10.33 - $14.49 $826 - $1,159	80 New	80 $1,000

228

79.1M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.33B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.